PMID- 31475172
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 7
IP  - 14
DP  - 2019 Jul
TI  - Anti-atherosclerotic effects between a combined treatment with simvastatin plus 
      hirudin and single simvastatin therapy in patients with early type 2 diabetes 
      mellitus.
PG  - 302
LID - 10.21037/atm.2019.05.69 [doi]
LID - 302
AB  - BACKGROUND: This study aimed to investigate the efficacy and safety of 
      simvastatin plus hirudin in preventing atherosclerosis in the patients with early 
      type 2 diabetes mellitus (T2DM). METHODS: This was a 24-week, randomized, 
      open-label and controlled study in which 150 outpatients initially diagnosed with 
      T2DM were randomly assigned into either simvastatin (40 mg daily at night) plus 
      hirudin (3 g thrice daily) group [combined group (CG) n=75] or simvastatin (40 mg 
      once daily) group [monotherapy group (MG) n=75]. The therapeutic efficacy was 
      evaluated by the score of carotid artery atherosclerosis, plaque size, peak 
      systolic velocity (PSV) and end-diastolic velocity (EDV) on carotid 
      ultrasonography at three and six months after treatment. Logistic regression 
      analysis was used to investigate the correlation between treatment and carotid 
      atherosclerosis. RESULTS: One hundred and thirty-one patients completed this 
      study, and there were no significant differences in the dropout rate in the CG 
      (14.67%) and the MG (10.67%). Significant difference was found in the incidence 
      of adverse events in the CG compared with the MG (37.50% vs. 17.91%, P<0.05) due 
      to the higher risk of hemorrhage (12.50% vs. 1.49%, P<0.05), which did not affect 
      the treatment compliance. The efficacy of combined treatment was better than 
      monotherapy in the enhancement of carotid artery atherosclerosis scores (P<0.01), 
      the plaque thickness (P<0.05) and the change of PSV (P<0.05) and EDV (P<0.05) 
      since three months after treatment, which maintained to the end of observation. 
      In addition, hirudin treatment was able to independently predict the carotid 
      artery atherosclerosis scores (beta=2.37, P<0.05), the plaque thickening (beta=3.51, 
      P<0.01) and the change of PSV (beta=1.69, P<0.05) and EDV (beta=1.79, P<0.05). 
      CONCLUSIONS: Combined use of simvastatin and hirudin is well tolerated and 
      possesses better anti-atherosclerotic effects than simvastatin alone in patients 
      with early T2DM.
FAU - Li, De-Qiang
AU  - Li DQ
AD  - Department of Integrated Internal Medicine, The First Affiliated Hospital of 
      Zhejiang University, Hangzhou 310003, China.
FAU - Lv, Fei-Fei
AU  - Lv FF
AD  - Department of Integrated Internal Medicine, The First Affiliated Hospital of 
      Zhejiang University, Hangzhou 310003, China.
FAU - Li, Zhong-Chun
AU  - Li ZC
AD  - Department of Neurology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, 
      China.
FAU - Dai, Zhi-Yuan
AU  - Dai ZY
AD  - Department of Preventive Medicine, Xiaoying Street Community Health Center, 
      Hangzhou 310002, China.
FAU - Wang, Hong-Xia
AU  - Wang HX
AD  - Department of Ultrasound Medicine, The First Affiliated Hospital of Zhejiang 
      University, Hangzhou 310003, China.
FAU - Han, Yang
AU  - Han Y
AD  - Department of Integrated Internal Medicine, The First Affiliated Hospital of 
      Zhejiang University, Hangzhou 310003, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC6694273
OTO - NOTNLM
OT  - Type 2 diabetes mellitus (T2DM)
OT  - atherosclerosis
OT  - hirudin
OT  - simvastatin
COIS- Conflict of Interests: The authors have no conflicts of interest to declare.
EDAT- 2019/09/03 06:00
MHDA- 2019/09/03 06:01
PMCR- 2019/07/01
CRDT- 2019/09/03 06:00
PHST- 2019/09/03 06:00 [entrez]
PHST- 2019/09/03 06:00 [pubmed]
PHST- 2019/09/03 06:01 [medline]
PHST- 2019/07/01 00:00 [pmc-release]
AID - atm-07-14-302 [pii]
AID - 10.21037/atm.2019.05.69 [doi]
PST - ppublish
SO  - Ann Transl Med. 2019 Jul;7(14):302. doi: 10.21037/atm.2019.05.69.